Aldeyra Plans Quick Response To FDA’s CRL For Reproxalap

 
• By Joseph Haas

Aldeyra already has a special protocol assessment under review at the FDA for a trial to provide the symptom data the agency said is needed for approval of the RASP modulator in dry eye disease.

Dry eye disease
Aldeyra hopes it can quickly refile its NDA for dry eye disease • Source: Shutterstock

More from New Products

More from Scrip